# Merck Sharp & Dohme LLC: Phase 1 study terminated, 30 enrolled (Advanced or Metastatic Solid Tumors)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) |
| NCT ID | NCT05382325 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | Advanced or Metastatic Solid Tumors |
| Intervention types | biological |
| Target enrollment | 30 |
| Site countries | United States, Canada, Israel, Netherlands |
| Posted | 2022-05-19 |
| Planned start | 2022-06-16 |
| Event | Terminated |
| Event date | 2026-09-29 |
| Last update posted | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05382325). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.